drugset / Trial / NCT01030939

Study to Investigate Safety, Tolerability, Pharmacokinetics and Cardiac Function After Repeat Doses of SB-649868 in Healthy-volunteers

NCT01030939

Phase 1 Completed 72 enrolled GlaxoSmithKline
RandomizedParallel-groupSingle-blindTreatment

Summary

The purpose of this study is to determine whether SB-649868 is safe, tolerable after repeated administrations in adult and elderly healthy volunteers. Pharmacokinetics and effects on cardiac function of repeated doses are studied

Timeline

Start
2009-08-27
Primary completion
2010-01-06
Completion
2010-01-06

Drugs

EvaluationDrugModalityDoseRoute
Subject SB-649868 Small molecule 20 mg Oral

Indications